{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:56:20Z","timestamp":1788393380464,"version":"build-2803163510"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ctrv.2025.102904","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T16:22:34Z","timestamp":1740068554000},"page":"102904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1\/CSF1R axis"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-5264","authenticated-orcid":false,"given":"Tarek","family":"Assi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Verret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"H\u00e9non","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile Le","family":"P\u00e9choux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rastilav","family":"Bahleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Vibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel Le","family":"Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.102904_b0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","article-title":"Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives","volume":"63","author":"Staals","year":"2016","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102904_b0010","first-page":"877","article-title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study","volume":"20","author":"Mastboom","year":"2019","journal-title":"LancetOncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102904_b0015","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.suronc.2018.07.002","article-title":"Severity classification of tenosynovial giant cell tumours on MR imaging","volume":"27","author":"Mastboom","year":"2018","journal-title":"Surg Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102904_b0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1148\/rg.285085134","article-title":"Pigmented villonodular synovitis: radiologic-pathologic correlation","volume":"28","author":"Murphey","year":"2008","journal-title":"Radiographics"},{"key":"10.1016\/j.ctrv.2025.102904_b0025","unstructured":"de St Aubain: Tenosynovial giant cell tumour, diffuse type - Google Scholar [Internet]. [cited 2024 Dec 10]. Available from: https:\/\/scholar.google.com\/scholar_lookup?title=Tenosynovial%20giant%20cell%20tumour%2C%20diffuse%20type&author=S.%20de%20St%20Aubain&publication_year=2013&pages=102-103."},{"issue":"1","key":"10.1016\/j.ctrv.2025.102904_b0030","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1186\/s12885-018-5188-6","article-title":"Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy","volume":"18","author":"Nakayama","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102904_b0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41379-018-0129-0","article-title":"Malignant tenosynovial giant cell tumor: The true \u201csynovial sarcoma?\u201d A clinicopathologic, immunohistochemical, and molecular cytogenetic study of 10 cases, supporting origin from synoviocytes","volume":"32","author":"Al-Ibraheemi","year":"2019","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102904_b0040","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors: a nationwide study in The Netherlands","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop"},{"key":"10.1016\/j.ctrv.2025.102904_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102491","article-title":"Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts","volume":"112","author":"Stacchiotti","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2025.102904_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-015-0385-x","article-title":"Current systemic treatment options for tenosynovial giant cell tumor\/pigmented villonodular synovitis: targeting the CSF1\/CSF1R axis","volume":"17","author":"Brahmi","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102904_b0055","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/1097-0142(19860215)57:4<875::AID-CNCR2820570432>3.0.CO;2-Y","article-title":"Giant cell tumor of the tendon sheath (nodular tenosynovitis): a study of 207 cases to compare the large joint group with the common digit group","volume":"57","author":"Ushijima","year":"1986","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102904_b0060","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00000478-200004000-00002","article-title":"Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease","volume":"24","author":"Somerhausen","year":"2000","journal-title":"Am J SurgPathol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102904_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121451","article-title":"Pigmented villonodular synovitis: a retrospective multicenter study of 237 cases","volume":"10","author":"Xie","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102904_b0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","article-title":"Tenosynovial giant cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors","volume":"51","author":"Palmerini","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102904_b0075","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","article-title":"Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides","volume":"31","author":"Cupp","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102904_b0080","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102904_b0085","first-page":"404","article-title":"Giant cell tumour of tendon sheath (localised nodular tenosynovitis): clinicopathological features of 71 cases","volume":"54","author":"Monaghan","year":"2001","journal-title":"J ClinPathol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102904_b0090","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12891-023-06730-1","article-title":"Imaging characteristics of tenosynovial giant cell tumors on 18F-fluorodeoxyglucose positron emission tomography\/computed tomography: a retrospective observational study","volume":"24","author":"Mizuta","year":"2023","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102904_b0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/cncr.10615","article-title":"Fine-needle aspiration cytology of articular and periarticular lesions","volume":"96","author":"Dodd","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.102904_b0100","unstructured":"Macrophage-Activating Factors\u2014Advances in Research and Application: 2012 Edition: ScholarlyBrief. ScholarlyEditions; 2012."},{"issue":"7","key":"10.1016\/j.ctrv.2025.102904_b0105","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0046-8177(97)90155-6","article-title":"Giant cell tumor of tendon sheath is a polyclonal cellular proliferation","volume":"28","author":"Vogrincic","year":"1997","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102904_b0110","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/PAS.0b013e3181a6d86f","article-title":"Clusterin is expressed in normal synoviocytes and in tenosynovial giant cell tumors of localized and diffuse types: diagnostic and histogenetic implications","volume":"33","author":"Boland","year":"2009","journal-title":"Am J SurgPathol"},{"key":"10.1016\/j.ctrv.2025.102904_b0115","unstructured":"who classification of bone and soft tissue tumors 2020 - Recherche Google [Internet]. [cited 2024 Dec 11]. Available from: https:\/\/www.google.fr\/search?q=who+classification+of+bone+and+soft+tissue+tumors+2020&sca_esv=636238c710bc0fc7&sxsrf=ADLYWILOx2y7idgcpvunhOOpFuhjqd2GFw%3A1733917559698&source=hp&ei=d3tZZ-ynJ-OakdUPydfz6QM&iflsig=AL9hbdgAAAAAZ1mJhzl9lNrrmBH2gFXYba4wd4RKxWLo&oq=who+2020+classification+of+soft+t&gs_lp=Egdnd3Mtd2l6IiF3aG8gMjAyMCBjbGFzc2lmaWNhdGlvbiBvZiBzb2Z0IHQqAggBMgYQABgWGB4yBhAAGBYYHjIGEAAYFhgeMgYQABgWGB4yBhAAGBYYHjIGEAAYFhgeMgYQABgWGB4yBhAAGBYYHjIGEAAYFhgeMgYQABgWGB5Iu15QAFiLRXAAeACQAQCYAWKgAacTqgECMzO4AQHIAQD4AQGYAiGgAuQTwgIEECMYJ8ICERAuGIAEGLEDGNEDGIMBGMcBwgILEAAYgAQYsQMYgwHCAg4QLhiABBixAxiDARjUAsICCBAAGIAEGLEDwgIIEC4YgAQYsQPCAgsQLhiABBixAxiDAcICDhAuGIAEGLEDGNEDGMcBwgINEC4YgAQY0QMYxwEYCsICBRAAGIAEwgIIEAAYgAQYywHCAggQABiABBiiBJgDAJIHBDMyLjGgB6j1AQ&sclient=gws-wiz."},{"issue":"14","key":"10.1016\/j.ctrv.2025.102904_b0120","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2106\/JBJS.18.01147","article-title":"Surgical treatment of localized-type tenosynovial giant cell tumors of large joints: a study based on a multicenter-pooled database of 31 international sarcoma centers","volume":"101","author":"Mastboom","year":"2019","journal-title":"JBJS"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102904_b0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jso.23220","article-title":"A multidisciplinary approach to giant cell tumors of tendon sheath and synovium\u2014a critical appraisal of literature and treatment proposal","volume":"107","author":"Van Der Heijden","year":"2013","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102904_b0130","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1302\/0301-620X.97B4.34907","article-title":"The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis","volume":"97","author":"Mollon","year":"2015","journal-title":"Bone Joint J"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102904_b0135","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.coc.0000239142.48188.f6","article-title":"Pigmented villonodular synovitis","volume":"29","author":"Mendenhall","year":"2006","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102904_b0140","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023794","article-title":"Long-term functional outcomes of diffuse pigmented villonodular synovitis of knee: the role of adjuvant radiotherapy","volume":"100","author":"Chien","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"10197","key":"10.1016\/j.ctrv.2025.102904_b0145","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"issue":"10445","key":"10.1016\/j.ctrv.2025.102904_b0150","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","article-title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Gelderblom","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.102904_b0155","doi-asserted-by":"crossref","unstructured":"Lin W, Xu D, Austin CD, et al. Function of CSF1 and IL34 in Macrophage Homeostasis, Inflammation, and Cancer. Front Immunol [Internet]. 2019 [cited 2024 Dec 12];10.","DOI":"10.3389\/fimmu.2019.02019"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102904_b0160","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00774-013-0476-3","article-title":"IL-34 and CSF-1: similarities and differences","volume":"31","author":"Nakamichi","year":"2013","journal-title":"J Bone MinerMetab"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102904_b0165","first-page":"1155","article-title":"A macrophage colony-stimulating factor receptor\u2013green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse","volume":"101","author":"Sasmono","year":"2003","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102904_b0170","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102904_b0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.ctrv.2025.102904_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107986","article-title":"Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: a TAM-pting approach","volume":"231","author":"Chamseddine","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102904_b0185","first-page":"2701","article-title":"HPMA\u2013copolymer nanocarrier targets tumor-associated macrophages in primary and metastatic breast cancer","volume":"16","author":"Zimel","year":"2017","journal-title":"Mol CancerTher"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102904_b0190","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102904_b0195","first-page":"533","article-title":"Colony-stimulating factors in inflammation and autoimmunity","volume":"8","author":"Hamilton","year":"2008","journal-title":"Nat RevImmunol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102904_b0200","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102904_b0205","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/1078-0432.CCR-21-2007","article-title":"Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT","volume":"28","author":"Tap","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102904_b0210","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.33312","article-title":"Long\u2010term outcomes of pexidartinib in tenosynovial giant cell tumors","volume":"127","author":"Gelderblom","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.102904_b0215","unstructured":"Research C for DE and. FDA approves pexidartinib for tenosynovial giant cell tumor. FDA [Internet]. 2019 [cited 2024 Dec 14];."},{"key":"10.1016\/j.ctrv.2025.102904_b0220","unstructured":"NCCN guidelines - Soft Tissue Sarcoma Version 2.2023."},{"key":"10.1016\/j.ctrv.2025.102904_b0225","unstructured":"European Panel Recommends Against Pexidartinib for Tenosynovial Giant Cell Tumor [Internet]. OncLive. 2020 [cited 2024 Dec 14]. Available from: https:\/\/www.onclive.com\/view\/european-panel-recommends-against-pexidartinib-for-tenosynovial-giant-cell-tumor."},{"issue":"5","key":"10.1016\/j.ctrv.2025.102904_b0230","doi-asserted-by":"crossref","first-page":"e863","DOI":"10.1002\/onco.13629","article-title":"Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors","volume":"26","author":"Lewis","year":"2021","journal-title":"The oncologist"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102904_b0235","first-page":"2098","article-title":"Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages","volume":"20","author":"Smith","year":"2021","journal-title":"Mol CancerTher"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102904_b0240","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-24-0103","article-title":"CSF1R inhibition in patients with advanced solid tumors or tenosynovial giant cell tumor: a phase I study of vimseltinib","volume":"30","author":"Gelderblom","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102904_b0245","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0959-8049(02)80600-1","article-title":"Pharmacology of imatinib (STI571)","volume":"38","author":"Buchdunger","year":"2002","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102904_b0250","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/annonc\/mdn033","article-title":"Complete response to imatinib in relapsing pigmented villonodular synovitis\/tenosynovial giant cell tumor (PVNS\/TGCT)","volume":"19","author":"Blay","year":"2008","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102904_b0255","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.26409","article-title":"Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis","volume":"118","author":"Cassier","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.102904_b0260","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.suronc.2020.08.030","article-title":"The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT","volume":"35","author":"Mastboom","year":"2020","journal-title":"Surg Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102904_b0265","doi-asserted-by":"crossref","first-page":"14551","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102904_b0270","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2045-3329-3-8","article-title":"Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib","volume":"3","author":"Stacchiotti","year":"2013","journal-title":"Clin Sarcoma Res"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102904_b0275","first-page":"639","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"LancetOncol"},{"key":"10.1016\/j.ctrv.2025.102904_b0280","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2022.06.028","article-title":"Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: long-term follow-up of nilotinib in TGCT","volume":"173","author":"Spierenburg","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.102904_b0285","unstructured":"FDA Grants Breakthrough Therapy Designation for Pimicotinib in TGCT [Internet]. OncLive. 2023 [cited 2024 Dec 13]. Available from: https:\/\/www.onclive.com\/view\/fda-grants-breakthrough-therapy-designation-for-pimicotinib-in-tgct."},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2025.102904_b0290","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1200\/JCO.2023.41.16_suppl.11559","article-title":"Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): Phase 1b update","volume":"41","author":"Yao","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102904_b0295","article-title":"MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients","volume":"1\u20138","author":"Niu","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2025.102904_b0300","unstructured":"Pimicotinib Topline Results | Merck [Internet]. [cited 2024 Dec 12]. Available from: https:\/\/www.merckgroup.com\/en\/news\/pimicotinib-topline-results-12-11-2024.html."},{"issue":"1","key":"10.1016\/j.ctrv.2025.102904_b0305","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s13577-022-00823-0","article-title":"Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis","volume":"36","author":"Thongchot","year":"2022","journal-title":"Hum Cell"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102904_b0310","first-page":"949","article-title":"CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study","volume":"16","author":"Cassier","year":"2015","journal-title":"LancetOncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102904_b0315","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cpt.1964","article-title":"PK\/PD mediated dose optimization of Emactuzumab, a CSF1R inhibitor, in patients with advanced solid tumors and diffuse\u2010type Tenosynovial giant cell tumor","volume":"108","author":"Smart","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2025.102904_b0320","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","article-title":"Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour","volume":"141","author":"Cassier","year":"2020","journal-title":"Eur J Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2025.102904_b0325","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS11585","article-title":"A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor","volume":"41","author":"Gelderblom","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102904_b0330","doi-asserted-by":"crossref","first-page":"S1226","DOI":"10.1016\/j.annonc.2022.07.1589","article-title":"1486MO The synovial and systemic pharmacokinetics and pharmacodynamics of intra-articular administration of the CSF1 receptor antibody AMB-05X in a phase II proof-of-concept trial in tenosynovial giant cell tumor","volume":"33","author":"Gelderblom","year":"2022","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2025.102904_b0335","doi-asserted-by":"crossref","first-page":"11078","DOI":"10.1200\/JCO.2017.35.15_suppl.11078","article-title":"A phase I\/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS)","volume":"35","author":"Sankhala","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102904_b0340","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3390\/medicina60101675","article-title":"Treatment modalities for refractory-recurrent tenosynovial giant cell tumor (TGCT): an update","volume":"60","author":"Dania","year":"2024","journal-title":"Medicina (Mex)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102904_b0345","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2005.11.006","article-title":"Colony-stimulating factor-1 in immunity and inflammation","volume":"18","author":"Chitu","year":"2006","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102904_b0350","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/0008-5472.CAN-06-2295","article-title":"Colon cancer cell\u2013derived tumor necrosis factor-\u03b1 mediates the tumor growth\u2013promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway","volume":"67","author":"Zins","year":"2007","journal-title":"CancerRes"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102904_b0355","first-page":"268","article-title":"Intra-articular etanercept treatment for severe diffuse pigmented villonodular knee synovitis","volume":"58","author":"Fiocco","year":"2006","journal-title":"Reumatismo"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102904_b0360","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00296-009-1185-z","article-title":"Intraarticular adalimumab in a patient with pigmented villonodular synovitis","volume":"31","author":"Kobak","year":"2011","journal-title":"Rheumatol Int"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102904_b0365","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/1756-185X.12585","article-title":"Refractory knee giant cell tumor of the synovial membrane treated with intra\u2010articular injection of Infliximab: a case series and review of the literature","volume":"18","author":"Praino","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102904_b0370","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12891-019-2453-z","article-title":"Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol","volume":"20","author":"Takeuchi","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102904_b0375","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/annrheumdis-2013-204589","article-title":"Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour","volume":"73","author":"Nissen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102904_b0380","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1158\/0008-5472.CAN-05-3523","article-title":"Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts","volume":"66","author":"Paulus","year":"2006","journal-title":"CancerRes"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102904_b0385","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102904_b0390","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102904_b0395","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102904_b0400","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-20-3955","article-title":"A randomized phase II study of anti-CSF1 monoclonal antibody lacnotuzumab (MCS110) combined with gemcitabine and carboplatin in advanced triple-negative breast cancer","volume":"28","author":"Kuemmel","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102904_b0405","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","article-title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages","volume":"30","author":"Gomez-Roca","year":"2019","journal-title":"Ann Oncol"},{"issue":"731","key":"10.1016\/j.ctrv.2025.102904_b0410","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add1834","article-title":"The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers","volume":"16","author":"Voissi\u00e8re","year":"2024","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102904_b0415","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/carcin\/bgac043","article-title":"CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model","volume":"43","author":"Omstead","year":"2022","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102904_b0420","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004076","article-title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients na\u00efve or experienced for immune checkpoint blockade","volume":"10","author":"Gomez-Roca","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722500026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722500026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T09:28:20Z","timestamp":1744190900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722500026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":84,"alternative-id":["S030573722500026X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102904","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1\/CSF1R axis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102904"}}